Organoids were utilized in chemo-sensitivity screens mimicking intravenous conditions during which these were treated with 5-fluorouracil (5-FU), oxaliplatin, irinotecan, FOLFOX, FOLFIRI, or regorafenib as described previously.11 (link) Stock solutions of 10 mM were prepared for 5-FU (F6627; Sigma), irinotecan (I1406; Sigma), and regorafenib (S1178; Selleckchem) by dissolving in dime-thyl sulfoxide (DMSO), while oxaliplatin and folinic acid (47612; Sigma-Aldrich) were dissolved in deionized H2O. Treatment solutions were prepared in cell culture media to the following concentrations: 10 μM 5FU, 1 μM oxaliplatin, 1 μM irinotecan, 1:10:1 μM folinic acid:5FU:oxaliplatin (FOLFOX), 1:10:1 μM folinic acid:5FU:oxaliplatin (FOLFIRI), and 1 μM regorafenib. After 7 days, spent media was removed from organoids, and treatments were added to the wells. Organoids were treated for 72 h, after which viability assays were performed.